Subject(s)
Skin/pathology , Antigens, CD1/analysis , Biopsy , Diagnosis, Differential , Humans , Immunohistochemistry , Keratosis/diagnosis , Keratosis/metabolism , Male , Middle Aged , Scleroderma, Localized/diagnosis , Scleroderma, Localized/metabolism , Skin/metabolism , Skin Neoplasms/diagnosis , Skin Neoplasms/metabolismABSTRACT
BACKGROUND: Infantile hemangiomas are benign vascular tumors that affect 8-12 % of infants. Several recent articles describe effect of propanolol in this patient group. We report a case and present a short review of the literature. MATERIAL AND METHODS: The article is based on literature retrieved through a non-systematic search in Pubmed, and our own experience in using propanolol for treatment of a patient with infantile hemangioma. RESULTS: Our patient responded quickly to propanolol, with a clinical response within few days. Literature describes reduced size and changes in the colour of hemangiomas within 24-48 hours. Our experience is in line with that reported in the literature. Propanolol treatment of this patient group has only been documented in observational studies of small groups and no prospective clinical studies have been reported. INTERPRETATION: Propanolol seems to be an effective treatment of infantile hemangiomas. Prospective controlled studies are needed to document optimal dosing, need for monitoring, side effects and duration of therapy.
Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Eye Neoplasms/drug therapy , Hemangioma/drug therapy , Propranolol/therapeutic use , Skin Neoplasms/drug therapy , Adrenergic beta-Antagonists/administration & dosage , Female , Humans , Infant , Neoplasms, Multiple Primary/drug therapy , Propranolol/administration & dosage , Time Factors , Treatment OutcomeSubject(s)
Adenoma, Sweat Gland , Mohs Surgery/methods , Receptors, Estrogen/metabolism , Sweat Gland Neoplasms , Adenoma, Sweat Gland/metabolism , Adenoma, Sweat Gland/pathology , Adenoma, Sweat Gland/surgery , Aged , Biomarkers, Tumor/metabolism , Diagnosis, Differential , Follow-Up Studies , Foot , Humans , Immunohistochemistry , Male , Sentinel Lymph Node Biopsy , Sweat Gland Neoplasms/metabolism , Sweat Gland Neoplasms/pathology , Sweat Gland Neoplasms/surgeryABSTRACT
Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by a C1-inhibitor deficiency. It is characterized by potentially life-threatening recurrent episodes of angioedema of the skin and mucosa. Several recent studies have further elucidated the immunology of HAE implicating bradykinin, the key mediator of the contact system. This article reviews the pathophysiology, subtypes, and clinical features of HAE. Therapeutic approaches for various clinical situations (emergency and prophylactic regimens) are also discussed.